MedTrace Logo

Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis

NCT02338635 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2015-05-15

No results posted yet for this study

Summary

Peritoneal fibrosis is one of the major causes of technical failure in patients on peritoneal dialysis (PD) for long period of time. Although the exact mechanisms of peritoneal damage during PD still remain unclear, generation of Endoplasmic reticulum (ER) stress may be responsible for progressive membrane dysfunction. Ursodeoxycholic acid (URSA) is a powerful inhibitor of ER stress to protect peritoneal fibrosis in peritoneal dialysis in the investigators in-vitro study. In this study the researchers investigated the hypothesis that URSA protect peritoneal membrane damage.

Conditions

  • End-Stage Kidney Disease

Interventions

DRUG

Ursodeoxycholic Acid

Inhibition of ER stress (Ursodeoxycholic Acid)

Sponsors & Collaborators

  • Ewha Womans University

    lead OTHER

Principal Investigators

  • Duk-Hee Kang, MD. PhD. · Ewha Womans University Mokdong Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2017-01-31
Completion
2018-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02338635 on ClinicalTrials.gov